Applied Information Aspects of Medicine (Prikladnye informacionnye aspekty mediciny)Applied Information Aspects of Medicine (Prikladnye informacionnye aspekty mediciny)2070-9277Voronezh State Medical University named after N.N. Burdenko - The State Budgetary Institution of Higher Professional Education «Voronezh State Medical University named after N.N. Burdenko» of the Ministry of Public Health of the Russian1010710.18499/2070-9277-2024-27-2-56-52Original ArticleIdentifiers of nitrosative stress in peripheral atherosclerosisKorotkovaNatalya Vasilevna<p>PhD, Associate Professor, Associate Professor of the Department of Biological Chemistry</p>fnv8@yandex.ruKalininNovel Evgenievich<p>MD, Professor, Head of the Department of Cardiovascular, X-ray Endovascular Surgery and Radiology</p>kalinin-re@yandex.ruSuchkovIgor Aleksandrovich<p>MD, Professor, Professor of the Department of Cardiovascular, X-ray Endovascular Surgery and Radiology</p>suchkov_med@mail.ruМжаванадзеNina Dzhansugovna<p>MD, Associate Professor, Professor of the Department of Cardiovascular, X-ray Endovascular Surgery and Radiology</p>nina_mzhavanadze@mail.ruNikiforovAlexander Alexeyevich<p>Head of the Central Research Institute</p>alnik003@yandex.ruFGBOU IN Ryazan State Medical University28062024272565208072024Copyright © 2024, Applied Information Aspects of Medicine (Prikladnye informacionnye aspekty mediciny)2024<p>Nitrosative stress is a component in the pathogenesis of many diseases, including the cardiovascular system. Toxic products formed as a result of the interaction of excessive amounts of nitric oxide (II) affect the structure of proteins, interacting with the functional groups of the latter, and disrupt the functioning of enzymes. As a result, nitrosative stress products are formed, which can be markers of the severity of the pathology. Peripheral atherosclerosis is a common pathology that leads to disability and mortality. The purpose of the presented study was to study markers of nitrosative stress in the blood serum of patients with peripheral atherosclerosis. Such indicators as the final metabolites of nitric oxide, nitrothyrosine, bityrosine, as well as the level of inducible and endothelial NO synthases were determined. An increase in the level of inducible NO synthase was revealed without changing the level of endothelial NO synthase, and a multidirectional change in the concentration of markers of nitrosative damage: an increase in the final metabolites of nitric oxide and nitrothyrosine, a decrease in the level of bityrosine crosslinking in the serum of patients with peripheral atherosclerosi</p>peripheral atherosclerosis, nitric oxide synthase, nitrothyrosine, bityrosine, nitric oxide (II) metabolitesпериферический атеросклероз, синтаза оксида азота, нитротирозин, битирозин, метаболиты оксида азота (II).[1. Martin W. Robert F. Furchgott, Nobel laureate (1916-2009)–a personal reflection. Br. J. Pharmacol. 2009; 158:633–637. DOI: 10.1111/j.1476-5381.2009.00418.x.][2. Bryan N.S. Nitric oxide deficiency is a primary driver of hypertension. Biochem Pharmacol. 2022;206:115325. DOI: 10.1016/j.bcp.2022.115325.][3. Hammond J., Balligand J.L. Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: From contractility to remodeling. J. Mol. Cell Cardiol. 2012; 52:330–340. DOI: 10.1016/j.yjmcc.2011.07.029.][4. Wang Z., Yang N., Hou Y., Li Y., Yin C., Yang E. L-Arginine-Loaded Gold Nanocages Ameliorate Myocardial Ischemia/Reperfusion Injury by Promoting Nitric Oxide Production and Maintaining Mitochondrial Function. Adv Sci (Weinh). 2023;10(26):e2302123. DOI: 10.1002/advs.202302123][5. Idigo W.O., Reilly S., Zhang M.H., Zhang Y.H., Jayaram R., Carnicer R. Regulation of endothelial nitric-oxide synthase (NOS) S-glutathionylation by neuronal NOS: Evidence of a functional interaction between myocardial constitutive NOS isoforms. J. Biol. Chem. 2012; 287: 43665–43673. DOI: 10.1074/jbc.M112.412031.][6. Cinelli M.A., Do H.T., Miley G.P., Silverman R.B. Inducible nitric oxide synthase: Regulation, structure, and inhibition. Med. Res. Rev. 2020; 40:158–189. DOI: 10.1002/med.21599.][7. Tegeder I. Nitric oxide mediated redox regulation of protein homeostasis. Cell Signal. 2019; 53:348–356. DOI: 10.1016/j.cellsig.2018.10.019.][8. Hou J., Yu K., Sunwoo K., Kim W., Koo S., Wang J. Fluorescent Imaging of Reactive Oxygen and Nitrogen Species Associated with Pathophysiological Processes. Chem. Res. Toxicol. 2020; 6:832–866. DOI:10.1016/j.chempr.2019.12.005.][9. Nordanstig J., Behrendt C.A., Bradbury A.W., de Borst G.J., Fowkes Fgr , Golledge J. et al. Peripheral arterial disease (PAD) - A challenging manifestation of atherosclerosis. Prev Med. 2023;171:107489. doi: 10.1016/j.ypmed.2023.107489. DOI: 10.1016/j.ypmed.2023.107489.][10. Калинин Р.Е., Сучков И.А., Климентова Э.А., Щулькин А.В., Пшенников А.С., Мыльников П.Ю., Егоров А.А. Показатели митохондриального пути апоптоза в сыворотке крови и гомогенате сосудистой стенки у пациентов с атеросклерозом периферических артерий. Наука молодых (Eruditio Juvenium). 2021;9(2):226-234. DOI:10.23888/HMJ202192226-234.][11. Калинин Р.Е., Сучков И.А., Климентова Э.А., Егоров А.А., Карпов В.В. Биомаркеры апоптоза и пролиферации клеток в диагностике прогрессирования атеросклероза в различных сосудистых бассейнах. Российский медико-биологический вестник им. академика И.П. Павлова. 2022; (30)2:243-252. DOI: 10.17816/PAVLOVJ88938][12. Метельская В.А., Н.Г. Гуманова. Скрининг-метод определения уровня метаболитов оксида азота в сыворотке крови человека. Клиническая лабораторная диагностика. 2005; 6:15-18. ISSN: 0869-2084.][13. Сорокина Е.Г., Радыгина Т.В., Реутов В.П., Бакаева З.В., Афанасьева С.А., Петричук С.В. и др. Окислительный стресс и модификация белков крови у детей с воспалительными заболеваниями кишечника. Российский педиатрический журнал. 2023;26(4):252-257. DOI:10.46563/1560-9561-2023-26-4-252-257.][14. Boer T.R., Palomino R.I., Mascharak P.K. Peroxynitrite-mediated dimerization of 3-nitrotyrosine: unique chemistry along the spectrum of peroxynitrite-mediated nitration of tyrosine. Med One. 2019; 4:e190003. DOI: 10.20900/mo.20190003.][15. Shah A.M. Inducible nitric oxide synthase and cardiovascular disease. Cardiovasc. Res. 2000;45(1):148-55. DOI: 10.1016/s0008-6363(99)00316-8.][16. Mungrue I.N., Gros R., You X., Pirani A., Azad A., Csont T. et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynutrite generation, heart block, and sudden death. J. Clin. Invest. 2002;109(6):735-43. DOI: 10.1172/JCI13265.][17. Zhang P., Xu X., Hu X., van Deel E.D., Zhu G., Chen Y. iNOS deficiency protects the heart from systolic overload induced ventricular hypertrophy and congestive heart failure. 2007;100(7):1089-98. DOI: 10.1161/01.RES.0000264081.78659.45.][18. Lind M., Hayes A., Caprnda M., Petrovic D., Rodrigo L., Kruzliak P., Zulli A. Inducible nitric oxide synthase: Good or bad? Biomed Pharmacother. 2017;(93):370-375. DOI: 10.1016/j.biopha.2017.06.036.]